NO20085098L - Behandling av ischemisks sykdommer ved bruk av erytropoietin - Google Patents
Behandling av ischemisks sykdommer ved bruk av erytropoietinInfo
- Publication number
- NO20085098L NO20085098L NO20085098A NO20085098A NO20085098L NO 20085098 L NO20085098 L NO 20085098L NO 20085098 A NO20085098 A NO 20085098A NO 20085098 A NO20085098 A NO 20085098A NO 20085098 L NO20085098 L NO 20085098L
- Authority
- NO
- Norway
- Prior art keywords
- subject
- erythropoietin
- treatment
- peripheral blood
- ischemic diseases
- Prior art date
Links
- 102000003951 Erythropoietin Human genes 0.000 title abstract 3
- 108090000394 Erythropoietin Proteins 0.000 title abstract 3
- 229940105423 erythropoietin Drugs 0.000 title abstract 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 3
- 208000023589 ischemic disease Diseases 0.000 title abstract 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 abstract 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006158998 | 2006-06-07 | ||
PCT/JP2007/061525 WO2007142288A1 (ja) | 2006-06-07 | 2007-06-07 | エリスロポエチンを用いた虚血性疾患の治療 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20085098L true NO20085098L (no) | 2009-02-27 |
Family
ID=38801534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20085098A NO20085098L (no) | 2006-06-07 | 2008-12-08 | Behandling av ischemisks sykdommer ved bruk av erytropoietin |
Country Status (17)
Country | Link |
---|---|
US (1) | US20090280094A1 (pt) |
EP (1) | EP2047859A4 (pt) |
JP (2) | JP5326079B2 (pt) |
KR (1) | KR20090031547A (pt) |
CN (1) | CN101460188B (pt) |
AR (1) | AR061269A1 (pt) |
AU (1) | AU2007255717B2 (pt) |
BR (1) | BRPI0712063A2 (pt) |
CA (1) | CA2654154A1 (pt) |
HK (1) | HK1128419A1 (pt) |
IL (1) | IL195648A0 (pt) |
MX (1) | MX2008015392A (pt) |
NO (1) | NO20085098L (pt) |
NZ (1) | NZ573792A (pt) |
RU (1) | RU2008152746A (pt) |
TW (1) | TW200815026A (pt) |
WO (1) | WO2007142288A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2654154A1 (en) * | 2006-06-07 | 2007-12-13 | The University Of Tokushima | Treatment of ischemic diseases using erythropoietin |
KR101811235B1 (ko) | 2009-06-05 | 2017-12-21 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | T 세포 및 조혈 세포의 재프로그래밍 |
FR2957799B1 (fr) * | 2010-03-26 | 2012-08-17 | Inst Des Vaisseaux Et Du Sang | Compositions proangiogeniques, leur procede de preparation et leurs utilisations |
CN101940590B (zh) * | 2010-08-27 | 2013-09-18 | 上海士腾生物技术有限公司 | 促进创伤愈合的制剂及其制备方法 |
CN101940594B (zh) * | 2010-08-27 | 2013-12-04 | 上海士腾生物技术有限公司 | 用于治疗缺血性心血管疾病的制剂及其制备方法 |
JP5582983B2 (ja) * | 2010-11-24 | 2014-09-03 | 楠本化成株式会社 | 水系沈降防止剤 |
KR101544674B1 (ko) * | 2013-06-05 | 2015-09-02 | 서울대학교산학협력단 | 에리쓰로포이에틴으로 프라이밍된 혈관 생성능이 향상된 말초혈액 줄기세포 및 그 용도 |
DE102017116204B4 (de) * | 2017-07-18 | 2024-06-27 | Universität Rostock | Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62501010A (ja) | 1984-12-04 | 1987-04-23 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | エリトロポエチンの生産方法 |
US4677195A (en) | 1985-01-11 | 1987-06-30 | Genetics Institute, Inc. | Method for the purification of erythropoietin and erythropoietin compositions |
KR100263845B1 (ko) | 1989-10-13 | 2000-08-16 | 스튜어트 엘.왓트 | 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물 |
TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
DE19857609A1 (de) * | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
EA012340B1 (ru) | 2001-10-29 | 2009-10-30 | Круселл Холланд Б.В. | Способ получения гликозилированной белковой молекулы, содержащей структуру lewis x, и/или сиалил-lewis x, и/или lacdinac |
US6784154B2 (en) * | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
US20040009908A1 (en) * | 2002-07-10 | 2004-01-15 | Stamler Jonathan S. | Methods for treating or preventing ischemic injury |
DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
US20050058622A1 (en) * | 2002-12-06 | 2005-03-17 | Lyman Stewart D. | Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens |
AU2004226372A1 (en) * | 2003-03-27 | 2004-10-14 | Janssen Pharmaceutica N.V. | Use of erythropoietin in stroke recovery |
CN1764470A (zh) * | 2003-03-27 | 2006-04-26 | 詹森药业有限公司 | 促红细胞生成素在中风康复中的用途 |
US20040198663A1 (en) * | 2003-04-04 | 2004-10-07 | Baker John E. | Method of treating cardiac ischemia by using erythropoietin |
DE102004004509B4 (de) * | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
JP2007217283A (ja) * | 2004-03-30 | 2007-08-30 | Niigata Tlo:Kk | 血管新生促進剤および血管新生療法 |
JP2006158998A (ja) | 2004-12-02 | 2006-06-22 | Nippon Sheet Glass Co Ltd | ロッドの反り選別装置 |
PT2540309T (pt) * | 2005-08-05 | 2017-12-29 | Araim Pharmaceuticals Inc | Péptidos protectores de tecidos e suas utilizações |
CA2654154A1 (en) * | 2006-06-07 | 2007-12-13 | The University Of Tokushima | Treatment of ischemic diseases using erythropoietin |
-
2007
- 2007-06-07 CA CA002654154A patent/CA2654154A1/en not_active Abandoned
- 2007-06-07 AR ARP070102478A patent/AR061269A1/es not_active Application Discontinuation
- 2007-06-07 TW TW096120549A patent/TW200815026A/zh unknown
- 2007-06-07 EP EP07744855A patent/EP2047859A4/en not_active Withdrawn
- 2007-06-07 NZ NZ573792A patent/NZ573792A/en not_active IP Right Cessation
- 2007-06-07 RU RU2008152746/15A patent/RU2008152746A/ru not_active Application Discontinuation
- 2007-06-07 MX MX2008015392A patent/MX2008015392A/es active IP Right Grant
- 2007-06-07 AU AU2007255717A patent/AU2007255717B2/en not_active Ceased
- 2007-06-07 JP JP2008520614A patent/JP5326079B2/ja active Active
- 2007-06-07 KR KR1020097000110A patent/KR20090031547A/ko not_active Application Discontinuation
- 2007-06-07 WO PCT/JP2007/061525 patent/WO2007142288A1/ja active Application Filing
- 2007-06-07 US US12/303,669 patent/US20090280094A1/en not_active Abandoned
- 2007-06-07 CN CN2007800209636A patent/CN101460188B/zh not_active Expired - Fee Related
- 2007-06-07 BR BRPI0712063-0A patent/BRPI0712063A2/pt not_active IP Right Cessation
-
2008
- 2008-12-02 IL IL195648A patent/IL195648A0/en unknown
- 2008-12-08 NO NO20085098A patent/NO20085098L/no not_active Application Discontinuation
-
2009
- 2009-08-20 HK HK09107647.3A patent/HK1128419A1/xx not_active IP Right Cessation
-
2013
- 2013-03-15 JP JP2013054102A patent/JP2013116919A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2047859A1 (en) | 2009-04-15 |
JP2013116919A (ja) | 2013-06-13 |
AU2007255717B2 (en) | 2013-07-11 |
JPWO2007142288A1 (ja) | 2009-10-29 |
TW200815026A (en) | 2008-04-01 |
RU2008152746A (ru) | 2010-07-20 |
WO2007142288A1 (ja) | 2007-12-13 |
MX2008015392A (es) | 2009-05-05 |
NZ573792A (en) | 2011-09-30 |
US20090280094A1 (en) | 2009-11-12 |
KR20090031547A (ko) | 2009-03-26 |
CA2654154A1 (en) | 2007-12-13 |
BRPI0712063A2 (pt) | 2011-12-20 |
CN101460188B (zh) | 2013-09-04 |
AR061269A1 (es) | 2008-08-13 |
EP2047859A4 (en) | 2010-05-05 |
IL195648A0 (en) | 2011-08-01 |
CN101460188A (zh) | 2009-06-17 |
JP5326079B2 (ja) | 2013-10-30 |
AU2007255717A1 (en) | 2007-12-13 |
HK1128419A1 (en) | 2009-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20085098L (no) | Behandling av ischemisks sykdommer ved bruk av erytropoietin | |
Gao et al. | Role of uremic toxin indoxyl sulfate in the progression of cardiovascular disease | |
Pouleur et al. | Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both | |
Tokuda et al. | Catheter ablation of ventricular tachycardia in nonischemic heart disease | |
Van Craenenbroeck et al. | Effect of moderate aerobic exercise training on endothelial function and arterial stiffness in CKD stages 3-4: a randomized controlled trial | |
Johnson et al. | Renal injury and salt-sensitive hypertension after exposure to catecholamines | |
Stein et al. | Safety and tolerability of dalcetrapib | |
Ishii et al. | Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment–elevation myocardial infarction | |
WO2012103025A3 (en) | Methods for obtaining single cells and applications of single cell omics | |
NZ596162A (en) | Pharmaceutical composition for the treatment of heart diseases | |
CN107075473A (zh) | 其中未分化细胞被去除的分化诱导的细胞群、其用途及其制备方法 | |
DE602005006990D1 (de) | Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen | |
Kiuchi et al. | New approaches in the management of sudden cardiac death in patients with heart failure—targeting the sympathetic nervous system | |
WO2008056368A3 (en) | Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases | |
El-Bassossy et al. | Cardioprotection by 6-gingerol in diabetic rats | |
Ueno et al. | Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel | |
WO2010123699A3 (en) | Compositions, kits and methods for promoting ischemic and diabetic wound healing | |
Cho et al. | Comparison of the effects of two low-density lipoprotein cholesterol goals for secondary prevention after acute myocardial infarction in real-world practice:≥ 50% reduction from baseline versus< 70 mg/dL | |
WO2008081447A3 (en) | Compounds and methods for detection of cells | |
Soares-Filho et al. | Broken heart or takotsubo syndrome: support for the neurohumoral hypothesis of stress cardiomyopathy | |
Sbarouni et al. | Clinical presentation and management of stable coronary artery disease: insights from the international prospective CLARIFY registry-results from the Greek national cohort | |
Vallès et al. | Novel Predictors For New Onset Atrial Fibrillation After Typical Atrial Flutter Ablation: An Invasive Prospective Study | |
Hayes et al. | [LB. 02.06] APPARENT AND TRUE TREATMENT RESISTANT HYPERTENSION IN GP: A CROSS SECTIONAL STUDY OF PREVALENCE WITH CONSIDERATION OF MORBIDITY, WHITE COAT HYPERTENSION, DOSING AND ADHERENCE | |
RU2006136460A (ru) | Способ индивидуального подбора иммунокоррегирующих препаратов для проведения иммунокоррегирующей терапии после трансплантации аутологичных стволовых клеток при лечении хронической сердечной недостаточности | |
Reverentia et al. | Effect of Short-Acting Loop Diuretics on 24-hour Heart Rate Variability and Blood Pressure in Patients with Acute Decompensated Heart Failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |